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The authors compare in their database including all patients with lung 
cancer since January 1990, the 160 patients included in 1990-5 (cohort 
A), and the 507 patients included in 2000-5 (cohort B).
The comparison shows, signiﬁcatively, an increase of number of lung 
cancer, an increase of women (A: 12 %, B: 25 %), of adenocarcinomas 
(A: 30 %, B: 53 %), of stage IV (A: 33 %, B: 44 %) and a reduction of 
squamous cell carcinomas (A: 41 %, B: 23 %), of stage IIIB ( A: 22 %, 
B: 12 %). Small cell lung cancer is stable (A: 11 %, B: 9 %).
Tobacco use is more important in cohort A (97%) than in B(92%). Age 
of both cohorts is the same (63.4 and 63.8 years)
In both cohorts, diagnosis is suspected in 77 % in front of symptoms.
The diagnosis is done in cohort A by endoscopy (70 %) and in cohort B 
by endoscopy (43%) and by CT-Transthoracic punction (20%).
Global survival is better in cohort B, 14.7 months, than in cohort A, 
10.7 months (p<0.002).
All TNM stages have a best survival in cohort B, but it is only sig-
niﬁcant for stage IV, PS 0-1 patients (B: 10.5 months, A: 6.7 months, 
p<0.0003) and for stage IIIB patients (B: 13.2 months, A: 9.3 months, 
p<0.0004). 
For the histology, for the gender, the difference are not signiﬁcant.
This best result seems due to a best selection of patients (Pet scan, RMI 
staging), to an increase of number of chemotherapy treatment in stage 
IV, in ﬁrst and second line, and to an use of third generation drugs. 
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Background: Women with advanced NSCLC tend to live longer than 
men for unclear reasons. A recent Southwest Oncology Group (SWOG) 
analysis of six trials of patients with advanced stage NSCLC (N=1334) 
again showed a survival advantage for women versus men, but interest-
ingly noted a cut-point for women around age 60, such that older wom-
en tended to live longer than younger women.(Albain IASLC-Chicago 
2006) Menopausal status was postulated as one explanation given the 
role of estrogen in lung cancer. To further explore this observation, we 
evaluated pooled data from two large ECOG trials, E1594 and E4599. 
Methods: E1594 randomized patients with advanced NSCLC to one of 
four platinum containing two-drug combination regimens, all of which 
had comparable efﬁcacy. E4599 randomized patients to carboplatin/pa-
clitaxel (one of the regimens on E1594) with or without bevacizumab. 
Because of confounding factors with bevacizumab, only the control 
arm is included in this analysis. Eligible patients from both E1594 
and the control arm of E4599 (N=1590) were divided into male and 
female cohorts and separated into age groups of < 60 or ≥ 60 years old. 
Survival was calculated separately for each cohort using the method of 
Kaplan-Meier. Known prognostic factors such as performance status, 
weight loss, and stage were also compared for each gender/age cohort 
using two-sided Fisher’s exact tests.
Results: 1590 eligible patients were included in this analysis consisting 
of 611 (38%) women and 979 (62%) men. 274 (45%) and 390 (40%) of 
women and men respectively were < 60 years old. A higher propor-
tion of those ≥ 60 were male (p=0.05), but there was no other statisti-
cally signiﬁcant differences in known prognostic factors between the 
4 gender/age cohorts. A statistically signiﬁcant difference in survival, 
however, was found. The median survival time (MST) for women ≥ 60 
years old was 11.6 months, versus 9.0 months for women < 60 (logrank 
p=.03). Men overall had lower survival than women, but no difference 
was seen for older men (MST of 7.4 months) versus men < 60 years 
old (MST of 8.3 months). Progression free survival (PFS) was also 
better for older women (4.7 months for those ≥ 60 years old versus 3.8 
months for younger women (logrank p =.009). Again no difference was 
seen for PFS for men of different ages, but men overall had shorter PFS 
than women.
Conclusions: As shown previously, women with advanced stage 
NSCLC live longer than men with the disease but the survival ad-
vantage is primarily for post-menopausal women at least 60 years of 
age. Known prognostic factors such as performance status, signiﬁcant 
weight loss, and stage cannot account for this difference. Men did 
not show a difference in survival by age. These data may indicate 
an important difference in lung cancer survival modiﬁed by meno-
pausal status. These data and the recent SWOG analysis make further 
investigation into the role of the estrogen pathway in lung cancer more 
compelling.
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Background: Histone methyltransferase (HMT) enzymes that methyl-
ate lysine residues of histone are involved in chromatin-mediated gene 
expression. The human homolog of the Drosophila gene Enhancer 
of Zeste 2 (EZH2) contains a highly conserved motif called the SET 
domain that required for the HMT activity. EZH2 has an important role 
in methylating histone H3 on Lys27, which leads to gene scilencing. 
Overexpression of the transcriptional repressor EZH2 was reported to 
be associated with the poor prognosis in various malignancies includ-
ing breast cancer and prostate cancer. In this study, we investigated the 
association between EZH2 polymorphisms and lung cancer risk. 
Materials and Methods: In a hospital-based study of 335 lung cancer 
patients and 335 age-, gender-matched healthy controls, 37 polymor-
phisms of EZH2 were examined. Of the 335 lung cancer patients, 189 
(56%) had adenocarcinomas, 77 (30%) had squamous cell carcinomas 
and 29 (9%) had small cell lung cancer. For a highly multiplexed SNP 
genotyping, the GoldenGate genotyping assay (Illumina Inc.) that 
combines an oligonucleotide ligation and allele-speciﬁc extension reac-
tion was performed. Statistical analyses were performed using logistic 
regression models with the adjustment for smoking status, pack-years 
and family history of cancer.
Results: All genotyped polymorphisms of EZH2 were in Hardy-Wein-
berg equilibrium in normal control population. When all age groups 
were analyzed together, one variant genotype of +19639A>G showed a 
signiﬁcant association with the reduced risk of lung cancer (AOR=0.72, 
